

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

For the month of: December 2018 (Report No. 3)

Commission file number: 001-36578

**BIOBLAST PHARMA LTD.**

(Translation of registrant's name into English)

PO Box 318, Tel-Aviv, Israel 6100201

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):

---

---

Attached hereto and incorporated into this Form 6-K is Exhibit 99.1, which includes unaudited financial information about Bioblast Pharma Ltd.'s (the "Registrant") as of and for the six months ended June 30, 2018. Exhibit 99.1 is furnished herewith solely for the purpose of meeting the requirements of Nasdaq Stock Market Rule 5250(c)(2) in connection with the submission of an interim balance sheet and income statement as of the end of the Registrant's second quarter.

Exhibit 99.1 attached to this Form 6-K of the Registrant is incorporated by reference into the registration statements on Form S-8 (File No. 333-203114 and File No. 333-210459) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**Exhibit No.**

99.1 Unaudited Financial Information as of and for the six months ended June 30, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bioblast Pharma Ltd.  
(Registrant)

By: /s/ Dr. Dalia Megiddo  
Name: Dr. Dalia Megiddo  
Interim Chief Executive Officer

Date: December 31, 2018

---



### Unaudited Financial Information as of and for the Six Months Ended June 30, 2018

In compliance with Nasdaq Stock Market Rule 5250(c)(2), Bioblast Pharma Ltd. (the "Company") hereby furnishes its unaudited consolidated statement of operations for the six months ended June 30, 2018 and its unaudited consolidated balance sheet as of June 30, 2018.

#### Consolidated Statement of Operations

(U.S. dollars in thousands, except share and per share amounts)

#### CONSOLIDATED STATEMENT OF OPERATIONS

U.S. dollars

	Six Months Ended	
	June 30 2018 (Unaudited)	June 30 2017 (Unaudited)
Research and development	\$ 159	\$ 1,982
Pre-commercialization	-	471
General and administrative	1,525	1,838
<b>Total operating expenses</b>	<b>1,684</b>	<b>4,291</b>
Loss from operations	(1,684)	(4,291)
Financial income, net	7	29
Loss before taxes on income	(1,677)	(4,262)
Taxes on income	17	43
Net loss	\$ (1,694)	\$ (4,305)
Net loss attributable to Ordinary shareholders	\$ (1,694)	\$ (4,305)
Net loss per share attributable to Ordinary shareholders - basic and diluted	\$ (0.50)	\$ (1.31)
Weighted average number of Ordinary shares outstanding - basic and diluted	3,356,523	3,284,489



Bioblast Pharma Ltd.

Consolidated Balance Sheet

(U.S. dollars in thousands, except share amounts)

**CONSOLIDATED BALANCE SHEET**

U.S. dollars

	<u>June 30, 2018</u>	<u>December 31, 2017</u>
	(Unaudited)	(Audited)
<b>ASSETS</b>		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 1,674	\$ 3,526
Short-term bank deposits	-	-
Receivables and prepaid expenses	30	96
Property and equipment, net	-	-
<u>Total current assets</u>	<u>1,704</u>	<u>3,622</u>
LONG-TERM ASSETS:		
	-	-
<b>TOTAL ASSETS</b>	<b><u>\$ 1,704</u></b>	<b><u>\$ 3,622</u></b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
CURRENT LIABILITIES:		
Trade payables	\$ 13	\$ 19
Other accounts payable	131	441
<u>Total current liabilities</u>	<u>144</u>	<u>460</u>
LONG-TERM LIABILITIES		
	-	-
SHAREHOLDERS' EQUITY:		
Ordinary shares of NIS 0.01 par value - 10,000,000 shares authorized at June 30, 2018 and December 31, 2017; Issued and outstanding shares 3,359,109 at June 30, 2018 and 3,342,393 at December 31, 2017	46	45
Additional paid-in capital	48,962	48,871
Accumulated deficit	(47,448)	(45,754)
<u>Total stockholders' equity</u>	<u>1,560</u>	<u>3,162</u>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b><u>\$ 1,704</u></b>	<b><u>\$ 3,622</u></b>